Investor's Business Daily7d agobullish
This Medical Technology Stock Claws Back To A Buy ZoneThis medical technology name has a patented method of drug delivery. Halozyme stock recently hit a record high with earnings due out soon.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
529last 24h
2502last 7d
477● bullish (7d)
254● bearish (7d)
197publishers
Zacks37d agobullish
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks41d agobullish
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks69d agobullish
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should WeighMyriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.
MT Newswires85d agobullish
Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan StanleyHalozyme Therapeutics (HALO) posted stronger-than-expected Q1 results, with revenue beating consensu
Zacks89d agobullish
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue EstimatesANI (ANIP) delivered earnings and revenue surprises of +60.16% and +15.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks90d agobullish
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue EstimatesImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Insider Monkey95d agobullish
Halozyme (HALO) Rated Buy on Strong Royalty GrowthHalozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now. On April 13, TD Cowen reaffirmed its Buy rating and $96 price target for Halozyme Therapeutics, Inc. (NASDAQ:HALO). The firm forecasts Halozyme to continue to outperform expectations and enhance guidance due to strong growth catalysts such as Vyvgart Hytrulo, Darzalex Faspro, […]
Simply Wall St.95d agobullish
How The Halozyme (HALO) Story Is Shifting Around Royalties Partnerships And Execution RiskHalozyme Therapeutics has seen its modelled Fair Value price target updated to $85.78 from $84.89, reflecting a modest recalibration in the latest assumptions. Analysts linking this change to current research point to royalty streams, ENHANZE collaborations, and acquired subcutaneous platforms as key factors shaping views on valuation and execution risk. As you read on, you will see how these moving pieces feed into the evolving narrative around Halozyme and what to watch next in the...
Zacks97d agobullish
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insider Monkey107d agobullish
Is Halozyme Therapeutics (HALO) One of the Most Undervalued Biotech Stocks to Buy Right Now?Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most undervalued biotech stocks to buy right now. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on April 7 that its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated. According to the collaboration, Vertex has licensed Halozyme Therapeutics’ (NASDAQ:HALO) Hypercon™ technology […]
Zacks112d agobullish
Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock?Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.